Bill
Bill > HR2873
summary
Introduced
04/28/2021
04/28/2021
In Committee
09/29/2021
09/29/2021
Crossed Over
Passed
Dead
01/03/2023
01/03/2023
Introduced Session
117th Congress
Bill Summary
A BILL To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
AI Summary
This bill, the Affordable Prescriptions for Patients Through Promoting Competition Act of 2021, amends the Federal Trade Commission Act to prohibit "product hopping." This refers to when a drug manufacturer withdraws an existing drug from the market or takes other actions to impede competition from generic or biosimilar versions, and then markets a new, modified version of the same drug. The bill establishes that this practice is an unfair method of competition, unless the manufacturer can demonstrate certain justifications related to safety or legitimate pro-competitive reasons. The bill gives the Federal Trade Commission the authority to investigate and take enforcement actions, including seeking disgorgement of unjust enrichment and restitution, against manufacturers that engage in this conduct.
Committee Categories
Justice
Sponsors (6)
David Cicilline (D)*,
Ken Buck (R),
Val Demings (D),
Carolyn Maloney (D),
Jerry Nadler (D),
Eleanor Holmes Norton (D),
Last Action
Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 27 - 16. (on 09/29/2021)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/117th-congress/house-bill/2873/all-info |
| BillText | https://www.congress.gov/117/bills/hr2873/BILLS-117hr2873ih.pdf |
| Bill | https://www.congress.gov/117/bills/hr2873/BILLS-117hr2873ih.pdf.pdf |
Loading...